Attendee search 

eADMET is an expert in the creation of customised computational models for the prediction of ADME/Tox properties of small drug-like molecules. eADMET’s modular approach combines proprietary and selected external algorithms to create customised prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

eADMET’s product portfolio includes:

1. OCHEM - a public accessible reference system and database
2. Validated models for precise prediction of various ADME/Tox parameters
3. User-friendly customized model solutions for specific customer needs
4. Expert consultancy services with respect to model application and interpretations.

New developments include chemogenomic methods and methods for in vitro to in vivo correlations to address toxicity prediction within drug discovery and REACH.

eADMET was founded as a result of GO-Bio project awarded to Dr Tetko with a financial support from High-Tech Gründerfonds (HTGF) and Bayern Kapital. it is a spinout from Helmholtz Centre, Munich.

APIM Therapeutics AS is a preclinical biotech company developing novel peptide anti-cancer drugs for various oncology indications. 

Targeting a novel, stress-induced therapeutic intevention point, the company’s current preclinical lead, ATX-101, sensitizes cancer cells to the action of >15 different chemotherapeutic drugs across multiple indications. The company has achieved proof-of-concept in selected in vivo and ex vivo cancer models of solid tumors (e.g. bladder, prostate) and blood cancer (myeloma, leukemia) in combination with >5 clinical drugs. 

APIM Therapeutics is venture capital financed. Current investors include Sarsia Seed, Birk Venture, Ro Invest and NIK. The company is seeking to raise additional funding in 2012-2013 in order to drive continuous preclinical development of ATX-101 to IND within a period of 18 months. 

Enterome is developing diagnostic products based on metagenomics of the human intestinal microbiota in patients with metabolic and inflammatory bowel diseases.

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees.

Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Launched in 2007 and backed by Santé Ventures, Terapio is a biopharmaceutical company developing clinical applications based on the naturally-occurring RLIP76 protein. RLIP76 is a membrane-associated cellular transport protein that is an integral part of the cell’s normal process of removing toxic metabolites formed by oxidative insults. However, in cases of elevated oxidative stress, such as occurs with exposure to radiation and chemical toxins, the endogenous RLIP76 system can be overwhelmed, leading to cell death. Supplementing cellular levels of RLIP76 through exogenous administration of Terapio’s liposomal formulation of the RLIP76 protein promotes protection by relieving this cellular stress and allows recovery by tissue cells. This mechanism of action has broad applicability to a variety of additional clinical indications, including the treatment of the toxic side effects of therapeutic radiation and chemotherapy in oncology patients and CNS diseases – a key part of Terapio’s commercial pipeline.

For biodefense applications, Terapio has accumulated a large body of data demonstrating that the protein is effective in protecting and rescuing animals exposed to otherwise lethal exposures of whole body radiation. Therefore, the company is pursuing the prevention and treatment of Acute Radiation Syndrome (ARS) as a lead indication. No effective countermeasures for ARS exist today, making this a highly unmet need.

Terapio has performed multiple 30-day survival studies with the RLIP76 protein in animal models of ARS and demonstrated that administered either before and/or after exposure to lethal doses of radiation results in greater than 90% survival of treated animals, versus 20% survival of controls.

Terapio is seeking a lead or syndicate investors to participate with Santé Ventures in Terapio’s Series B financing. Terapio plans at least $10M in Series B financing where Santé Ventures, the Series A lead investor, will participate on a pro rata basis. The use of proceeds for Series B will be primarily used for drug development, preclinical and nonclinical programs, and regulatory activities required to fund the company to the valuation inflection point associated with completing the pivotal nonhuman primate efficacy trial under the FDA Animal Rule.

PSites Pharma is developing the next generation of protein kinase inhibitors. Based on our discovery of a new non-ATP competitive, regulatory  binding site we had build up during the last 12 years a whole proprietary development platform, consisting of a focused library, a special screening and a crystallography platform. This allows us to develop clinical candidates for kinase inhibitors with specificities unknown for small coumpounds for any given ACG kinase target within 3 years.

Psites´s own lead compounds for oncology indications (lung and prostate cancer) had been successfully tested in mice and show a very good safety profile.

Our next financing round which is supported by a EUR 3 M. grant by the German governement will enable us to bring 2 compounds into the clinic and we are looking for partners who will share part of the development costs.

Alternatively we are also offering development collaborations for industrial partners who are interested in getting allosteric compounds for their specific target.

Edinburgh BioQuarter is the commercialisation arm of the University of Edinburgh Medical School and Veterinary College. We have recently spun out several companies in the devices, informatics and CRO space. Current companies in incubation include:

• FibromEd, which is developing improved hepatocyte products for drug toxicity testing
• Asclepius, an orphan drug company focused on rare renal disease
• Edinburgh Molecular Imaging, a new imaging technology focused on rapid diagnosis of lung pathology including fibrosis
• Therapivo, a new approach to the treatment of metastatic cancer based on phenotypic drug development
• Vaccine company which is utilising novel adjuvant technology
• Anti-infective company with broad spectrum anti-viral technolgy focused on respiratory infections